A carregar...
Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study
Background: Sorafenib, a multi-kinase inhibitor, is approved for the treatment of patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). This study evaluated the efficacy and safety of sorafenib in real-world clinical practice and compared the results to those of the...
Na minha lista:
| Publicado no: | Thyroid |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Mary Ann Liebert, Inc., publishers
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6225595/ https://ncbi.nlm.nih.gov/pubmed/29350109 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2017.0356 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|